{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:42:37Z","timestamp":1785498157251,"version":"3.56.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":769,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alcohol Clin Exp Res"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1111\/acer.12193","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T22:31:11Z","timestamp":1374705071000},"page":"27-32","source":"Crossref","is-referenced-by-count":17,"title":["Research Opportunities for Medications to Treat Alcohol Dependence: Addressing Stakeholders' Needs"],"prefix":"10.1111","volume":"38","author":[{"given":"Raye Z.","family":"Litten","sequence":"first","affiliation":[{"name":"NIAAA's Collaborative Investigator Group (NCIG), Division of Treatment and Recovery Research; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Falk","sequence":"additional","affiliation":[{"name":"NIAAA's Collaborative Investigator Group (NCIG), Division of Treatment and Recovery Research; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ryan","sequence":"additional","affiliation":[{"name":"NIAAA's Collaborative Investigator Group (NCIG), Division of Treatment and Recovery Research; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Fertig","sequence":"additional","affiliation":[{"name":"NIAAA's Collaborative Investigator Group (NCIG), Division of Treatment and Recovery Research; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"key":"10.1111\/acer.12193-BIB0001|acer12193-cit-0001","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0197-2456(98)00005-1","article-title":"Drug compliance in therapeutic trials: a review","volume":"19","author":"Boudes","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1111\/acer.12193-BIB0002|acer12193-cit-0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1124\/mi.11.2.8","article-title":"The secrets of a successful clinical trial: compliance, compliance, and compliance","volume":"11","author":"Czobor","year":"2011","journal-title":"Mol Interv"},{"key":"10.1111\/acer.12193-BIB0003|acer12193-cit-0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1360-0443.2004.00964.x","article-title":"Recovery from DSM-IV alcohol dependence: United States, 2001-2002","volume":"100","author":"Dawson","year":"2005","journal-title":"Addiction"},{"key":"10.1111\/acer.12193-BIB0004|acer12193-cit-0004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11920-012-0314-7","article-title":"Treatment of the depressed alcoholic patient","volume":"14","author":"DeVido","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"10.1111\/acer.12193-BIB0005|acer12193-cit-0005","unstructured":"European Medicines Agency 2010 Guideline on the development of medicinal products for the treatment of alcohol dependence http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/03\/WC500074898.pdf"},{"key":"10.1111\/acer.12193-BIB0006|acer12193-cit-0006","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1530-0277.2010.01290.x","article-title":"Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials","volume":"34","author":"Falk","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12193-BIB0007|acer12193-cit-0007","first-page":"21","volume-title":"Medical Review of Vivitrol","author":"FDA","year":"2006"},{"key":"10.1111\/acer.12193-BIB0008|acer12193-cit-0008","first-page":"79","article-title":"The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence","volume":"29","author":"Grant","year":"2006","journal-title":"Alcohol Res Health"},{"key":"10.1111\/acer.12193-BIB0009|acer12193-cit-0009","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrn3110","article-title":"Pharmacogenetic approaches to the treatment of alcohol addiction","volume":"12","author":"Heilig","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1111\/acer.12193-BIB0010|acer12193-cit-0010","unstructured":"IMS Health 2010 Danbury, CT http:\/\/www.imshealth.com"},{"key":"10.1111\/acer.12193-BIB0011|acer12193-cit-0011","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","article-title":"Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings","volume":"75","author":"Johnson","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/acer.12193-BIB0012|acer12193-cit-0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/scientificamerican0811-16","article-title":"A dearth of new meds","volume":"305","author":"Kaitin","year":"2011","journal-title":"Sci Am"},{"issue":"Suppl 1","key":"10.1111\/acer.12193-BIB0013|acer12193-cit-0013","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1111\/j.1530-0277.2012.01908.x","article-title":"Postreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders","volume":"37","author":"Kline-Simon","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12193-BIB0014|acer12193-cit-0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","article-title":"Adoption and implementation of medications in addiction treatment programs","volume":"5","author":"Knudsen","year":"2011","journal-title":"J Addict Med"},{"key":"10.1111\/acer.12193-BIB0015|acer12193-cit-0015","unstructured":"Levine DS 2012 Drug development: new estimate of drug development costs pegs total at $1.5 billion"},{"key":"10.1111\/acer.12193-BIB0016|acer12193-cit-0016","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1530-0277.2010.01170.x","article-title":"Alcohol biomarkers in applied settings: recent advances and future research opportunities","volume":"34","author":"Litten","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12193-BIB0017|acer12193-cit-0017","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addict Biol"},{"key":"10.1111\/acer.12193-BIB0018|acer12193-cit-0018","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty","volume":"99","author":"Mark","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/acer.12193-BIB0019|acer12193-cit-0019","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding US addiction physicians' low rate of naltrexone prescription","volume":"71","author":"Mark","year":"2003a","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/acer.12193-BIB0020|acer12193-cit-0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1360-0443.2003.00377.x","article-title":"Physicians' opinions about medications to treat alcoholism","volume":"98","author":"Mark","year":"2003b","journal-title":"Addiction"},{"key":"10.1111\/acer.12193-BIB0021|acer12193-cit-0021","volume-title":"Helping Patients Who Drink Too Much: A Clinician's Guide","author":"NIAAA","year":"2007"},{"key":"10.1111\/acer.12193-BIB0022|acer12193-cit-0022","volume-title":"Rethinking Drinking","author":"NIAAA","year":"2009"},{"key":"10.1111\/acer.12193-BIB0023|acer12193-cit-0023","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","article-title":"Barriers to use of pharmacotherapy for addiction disorders and how to overcome them","volume":"13","author":"Oliva","year":"2011","journal-title":"Curr Psychiatry Rep"},{"key":"10.1111\/acer.12193-BIB0024|acer12193-cit-0024","first-page":"300","article-title":"Medications for unhealthy alcohol use: across the spectrum","volume":"33","author":"O'Malley","year":"2011","journal-title":"Alcohol Res Health"},{"key":"10.1111\/acer.12193-BIB0025|acer12193-cit-0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/acer.12193-BIB0026|acer12193-cit-0026","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/alcalc\/agh171","article-title":"A critical review of pharmacoeconomic studies of acamprosate","volume":"40","author":"Poldrugo","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12193-BIB0028|acer12193-cit-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice: adoption of naltrexone in alcoholism treatment","volume":"24","author":"Thomas","year":"2003","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/acer.12193-BIB0027|acer12193-cit-0027","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jsat.2007.11.001","article-title":"Improving acceptance of naltrexone in community addiction treatment centers: a pilot study","volume":"35","author":"Thomas","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/acer.12193-BIB0029|acer12193-cit-0029","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/archpsyc.65.10.1214","article-title":"Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients","volume":"65","author":"Zarkin","year":"2008","journal-title":"Arch Gen Psychiatry"}],"container-title":["Alcoholism: Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facer.12193","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/acer.12193\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T17:10:55Z","timestamp":1625505055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acer.12193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1111\/acer.12193","relation":{},"ISSN":["0145-6008"],"issn-type":[{"value":"0145-6008","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,24]]}}}